aod-9604 vs tirzepatide for weight loss Semaglutide: 0% vs 15% Fat (2026 Data) AOD-9604 vs MOTS-c vs Tesamorelin

Ozempic and Semaglutide Ozempic and Semaglutide, both prominent members of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class, have demonstrated significant benefits in weight management, as supported by robust clinical evidence

The results were staggering

There is a scenario where the combination makes more sense: someone who has completed a tirzepatide protocol, achieved their primary weight loss goal, and is transitioning off the compound

Answer 6 questions and see typical peptides, dosing, injection schedule, reconstitution steps, cycle length, and when patients pause

The marginal benefit of adding AOD 9604 to a protocol that is already delivering 20%+ body weight reduction is questionable

AOD 9604 demonstrated virtually no significant adverse effects across all human trials at doses up to 1mg per day